GLP-1 WEIGHT LOSS PEPTIDES: BENEFITS AND COMPARISONS EDUCATIONAL INSIGHT

IMPORTANT NOTICE

FOR RESEARCH AND EDUCATIONAL PURPOSES ONLY

• FDA-approved medications (Ozempic®, Wegovy®, Mounjaro®, Zepbound®) require a doctor’s prescription
• Research peptides sold as chemicals are NOT approved for human use
• Retatrutide is still in clinical trials, not approved
• This document is for education only, not medical advice

WHAT ARE GLP-1 PEPTIDES?

GLP-1 (Glucagon-Like Peptide-1) is a hormone your body naturally makes when you eat. It tells your body to feel full, stop eating, and control blood sugar.

Scientists created medications that copy this hormone but last much longer. Originally made for diabetes, they turned out to be the most effective weight loss medications ever developed.

THE THREE GENERATIONS

Semaglutide > Targets 1 hormone > 15-17% weight loss

Tirzepatide > Targets 2 hormones > 20-22% weight loss

Retatrutide >Targets 3 hormones > 24% weight loss (in trials)

Each generation works better by targeting more pathways in your body.

THE THREE COMPOUNDS

SEMAGLUTIDE (OZEMPIC®, WEGOVY®)

Status: FDA-approved 2021 for weight loss

How it works: Copies GLP-1 hormone to reduce appetite and slow digestion

Research: STEP trials with nearly 5,000 people [1,2]

KEY RESULTS:

• Average weight loss: 15% of body weight (68 weeks)
• 86% of people lost at least 5% of their weight
• 50% of people lost at least 15% of their weight
• Reduced heart attacks/strokes by 20% (SELECT trial) [7]

Unique features: Available as weekly injection OR daily pill; most proven long-term safety data

TIRZEPATIDE (MOUNJARO®, ZEPBOUND®)

Status: FDA-approved 2023 for weight loss

How it works: Targets GLP-1 + GIP (two hormones work together)

Research: SURMOUNT trials with over 3,500 people [3,4,5]

KEY RESULTS:

• Average weight loss: 21% of body weight (72 weeks)
• 91% of people lost at least 5% of their weight
• 57% of people lost at least 20% of their weight
• Proven superior to semaglutide in head-to-head trial [4]

Unique features: Better weight loss than semaglutide; weekly injection only

RETATRUTIDE (INVESTIGATIONAL)

Status: Phase 3 clinical trials (NOT approved)

How it works: Targets GLP-1 + GIP + Glucagon (three hormones)

Research: Phase 2 trial with 338 people [6]

KEY RESULTS:

• Average weight loss: 24% of body weight (48 weeks)
• 92% of people lost at least 5% of their weight
• 60% of people lost at least 20% of their weight
• 27% of people lost at least 25% of their weight

Unique features: Highest weight loss ever seen; may burn more calories and preserve muscle better; possible approval 2026-2027

QUICK COMPARISON

HOW THEY WORK – SIMPLE EXPLANATION

Think of your body’s appetite system like a control panel with different switches:

Semaglutide: Flips 1 switch

• Reduces hunger in your brain
• Makes you feel full faster
• Slows digestion

Tirzepatide: Flips 2 switches

• Everything semaglutide does
• PLUS improves fat processing
• PLUS enhances insulin sensitivity

Retatrutide: Flips 3 switches

• Everything tirzepatide does
• PLUS increases calories burned
• PLUS helps preserve muscle

Why more is better: By targeting multiple pathways, each generation produces better results.

RESEARCH FINDINGS SUMMARY

WEIGHT LOSS COMPARISON

Example: 200 lb person

• Placebo: Lost 4-6 lbs
• Semaglutide: Lost 30 lbs (15%)
• Tirzepatide: Lost 42 lbs (21%)
• Retatrutide: Lost 48 lbs (24%)

OTHER HEALTH BENEFITS DOCUMENTED

• Blood sugar control: 1.5-2.5% A1C reduction
• Blood pressure: 5-10 point decrease
• Cholesterol: 15-30% improvement
• Liver fat: Significant reduction
• Heart health: Lower cardiovascular risk

COMMON SIDE EFFECTS

Most common: Nausea (20-45%), diarrhea (15-30%), vomiting (6-15%)

IMPORTANT NOTES:

• Usually mild to moderate
• Worst in first few months, then improve
• Serious side effects rare (<1%)

MARKET STATISTICS

MARKET SIZE AND GROWTH

2020: $6 billion

2023: $24 billion

2024: $35-40 billion (estimated)

2030: $100-150 billion (projected) [8,9]

This is one of the fastest-growing drug categories in pharmaceutical history.

MARKET SHARE BREAKDOWN (2024)

Total Weight Loss Medication Market: ~$25 billion

Key Finding: GLP-1 medications control 85-90% of the prescription weight loss market.

PRESCRIPTION GROWTH (UNITED STATES)

• 2019: 1 million prescriptions
• 2021: 5 million (semaglutide approved for weight loss)
• 2023: 18 million (tirzepatide approved)
• 2024: 25-30 million (estimated)

Current users: 5-7 million Americans

WHO MAKES THEM?

Two companies dominate:

Novo Nordisk (Semaglutide)

• Makes Ozempic® and Wegovy®
• Became Europe’s most valuable company (2024)

Eli Lilly (Tirzepatide & Retatrutide)

• Makes Mounjaro® and Zepbound®
• Developing retatrutide

Combined market control: Over 85%

Cost and Coverage

Retail Price: $1,000-1,400 per month ($12,000-16,800 per year)

Insurance Coverage (2024):

• 40-50% of commercial plans cover for weight loss
• Medicare does NOT cover (by law)
• Medicaid varies by state

FUTURE OUTLOOK

What’s Coming (2024-2030)

Near-Term (2024-2026):

• Retatrutide approval: Expected 2026-2027 (if successful)
• Oral medications: Multiple companies developing pill versions
• CagriSema: New combination showing 25% weight loss in trials
• Increased competition: Several new medications entering trials

MARKET PROJECTIONS:

• 2030 market size: $100-150 billion
• Users by 2030: 25-40 million Americans (currently 5-7 million)

EXPANDING MEDICAL USES

These medications are being tested for:

• Heart disease: Semaglutide already proven to prevent heart attacks [7]
• Liver disease: Reducing fatty liver (NASH)
• Kidney disease: Showing protective effects
• Sleep apnea: Weight loss improves breathing
• Alzheimer’s: Early research on brain benefits
• Addiction: May reduce alcohol/substance cravings

COMPETITION INCREASING

New companies developing GLP-1 medications:

• Amgen, Pfizer, Boehringer Ingelheim, Viking Therapeutics
• Multiple oral versions in development
• Generic versions possible in 2030s

What this means: More options and eventually lower prices

KEY CHALLENGES

Long-term considerations:

• Weight returns if you stop taking them
• Need lifelong treatment
• Long-term safety data still limited (most studies <2 years)
• Some muscle loss along with fat
• High costs limit access

BOTTOM LINE

What These Medications Represent

Breakthrough in weight loss:

• Most effective medications ever developed (15-24% weight loss)
• First treatments that rival weight loss surgery
• Work better with each generation (single –>dual –> triple hormone targeting)

Market dominance:

• Control 85-90% of weight loss medication market
• $35-40 billion market in 2024
• Projected to reach $100-150 billion by 2030
• Fastest-growing pharmaceutical category

Beyond weight loss:

• Cardiovascular benefits proven (20% reduction in heart attacks) [7]
• Diabetes prevention and management
• Multiple other health benefits documented

THE FUTURE:

• More medications coming (retatrutide likely 2026-2027)
• Oral options in development
• New medical uses being discovered
• Prices may eventually decrease with competition
• Could help millions more people

Important Limitations

• Very expensive ($12,000-16,000/year)
• Lifelong treatment needed
• Limited long-term safety data
• Not everyone responds equally
• Access limited by cost and insurance

REFERENCES

• [1] Marso SP, et al. “Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.” New England Journal of Medicine. 2016;375:1834-1844.
• [2] Wilding JPH, et al. “Once-Weekly Semaglutide in Adults with Overweight or Obesity.” New England Journal of Medicine. 2021;384:989-1002.

STEP 1 trial: 14.9% average weight loss

• [3] Rosenstock J, et al. “Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide (SURPASS-1).” The Lancet. 2021;398:143-155.
• [4] Frías JP, et al. “Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.” New England Journal of Medicine. 2021;385:503-515.

SURPASS-2: Tirzepatide superior to semaglutide

• [5] Jastreboff AM, et al. “Tirzepatide Once Weekly for the Treatment of Obesity.” New England Journal of Medicine. 2022;387:205-216.

SURMOUNT-1: Up to 20.9% weight loss

• 6] Jastreboff AM, et al. “Triple-Hormone-Receptor Agonist Retatrutide for Obesity.” New England Journal of Medicine. 2023;389:514-526.

Phase 2: Up to 24.2% weight loss

• [7] Lincoff AM, et al. “Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.” New England Journal of Medicine. 2023;389:2221-2232.

SELECT trial: 20% reduction in cardiovascular events

• [8] Morgan Stanley Research. “GLP-1 Drugs Market Analysis.” 2024.

Market projections: $100-150 billion by 2030

• [9] Goldman Sachs Equity Research. “The Future of GLP-1 Agonists.” 2024.

Growth rate: 30-40% annually through 2030

DOCUMENT INFORMATION

Purpose: Educational overview of GLP-1 weight loss peptides

Intended for: Researchers, students, healthcare professionals, general education

Version: 1.0 | Date: 2025

This document is intended for:

• Scientific researchers and academics
• Educational institutions
• Healthcare professionals
• Students and general education
• Market analysts and industry professionals

This document is NOT intended to:

• Provide medical advice or treatment recommendations
• Suggest use of non-FDA-approved research chemicals
• Replace consultation with licensed medical professionals
• Encourage off-label use of any medication

Important: FDA-approved medications require a prescription from a physician. Research peptides are not approved for human use. All information is from published scientific literature for educational purposes only.